Niacin for Cholesterol: Still Relevant?

Alan discovered flush-form niacin in the same place most people discover questionable health information: a YouTube rabbit hole at 11 PM. The premise was compelling — high-dose niacin could raise HDL dramatically, lower triglycerides, even reduce Lp(a). All from a B vitamin. He ordered 2g capsules, took three the first night, and woke up at 2 AM convinced he was having a stroke. Face, neck, chest bright red, burning, tingling. He nearly called 911. It wasn’t a stroke. It was a niacin flush — a prostaglandin-mediated vasodilation response so intense that even people who know exactly what it is find it alarming the first time. Alan pushed through, titrated up to 3g daily, and three months later his HDL had risen from 38 to 51 mg/dL. He was impressed. Then the AIM-HIGH trial results were published, and his cardiologist walked him through what the data actually said.

Niacin — vitamin B3 in its nicotinic acid form — has one of the more complicated stories in lipid medicine. It was one of the first lipid-modifying therapies ever studied (the Coronary Drug Project in the 1970s), showed genuine promise for decades, and then crashed spectacularly against randomized controlled trial evidence once it was finally tested in modern combination-therapy settings. Understanding what happened to niacin’s clinical reputation — what it does, what it doesn’t, and whether it’s worth considering at all — requires walking through the data rather than accepting either the enthusiast’s narrative or the dismissal.

What Niacin Does to Lipids

Niacin at pharmacological doses (1.5-6g daily — far above the dietary reference intake of 14-16mg) produces a distinct lipid profile modification that no other single intervention replicates:

1. Raises HDL-C 20-35%: The most dramatic HDL-C raising effect of any known intervention, including exercise and alcohol. Dose-dependent, consistent.
2. Lowers triglycerides 30-50%: Potent triglyceride-lowering, comparable to or exceeding fibrate drugs and high-dose omega-3s.
3. Lowers Lp(a) 20-30%: One of very few interventions that reliably reduces this largely genetic, notoriously treatment-resistant particle.
4. Lowers LDL-C 10-20%: Modest LDL reduction through inhibition of hepatic VLDL synthesis, which reduces LDL production downstream.
5. Lowers VLDL: Directly inhibits hepatic VLDL particle secretion — the upstream step in LDL production.

The mechanism behind HDL-C raising: niacin inhibits a hepatic cell surface protein called HCAR2 (formerly GPR109A), which normally triggers uptake and degradation of HDL-associated ApoA-I. Inhibit that receptor, and HDL-ApoA-I catabolism slows, letting HDL particles persist longer in circulation. It’s also the same receptor mediating niacin’s flush — which is exactly why flush and HDL raising travel together, and why “flush-free” forms that skip this receptor also skip the HDL effect.

The mechanistic picture was compelling enough — simultaneously raising the “good” cholesterol, lowering the “bad,” cutting triglycerides, and lowering the notoriously stubborn Lp(a) — that niacin became the logical candidate for a major cardiovascular outcomes trial in the modern statin era.

AIM-HIGH and HPS2-THRIVE — the Trials That Changed Everything

The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes), published in the New England Journal of Medicine in 2011, enrolled 3,414 patients with established cardiovascular disease already on simvastatin achieving LDL below 70-80 mg/dL. Randomized to extended-release niacin (Niaspan) 1500-2000mg daily or placebo. The niacin group showed all the expected lipid improvements — HDL rose, triglycerides fell. And then the trial got stopped early. Not because of benefit. Because there was clearly none on the primary cardiovascular endpoint (composite of coronary events, stroke, revascularization), and a possible increase in ischemic stroke in the niacin group.

The early termination drew criticism — the trial may have been underpowered, cut short before reaching its planned sample size. Defenders of niacin argued it didn’t prove harm, just a lack of incremental benefit on top of already-excellent statin therapy. Fair point, as far as it went.

Then came HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events), published in 2014, also in NEJM. Larger — 25,673 patients — using extended-release niacin combined with laropiprant (a prostaglandin receptor antagonist that reduces flushing), added to intensive statin therapy. The results were decisively negative: no reduction in cardiovascular events, and significantly increased adverse effects including myopathy, liver enzyme abnormalities, infections, and impaired glucose control. The niacin/laropiprant combination was pulled from European markets after this trial.

Taken together, AIM-HIGH and HPS2-THRIVE genuinely falsify the hypothesis that HDL-C raising with niacin reduces cardiovascular events when added to effective statin therapy. Not a minor finding. It fundamentally challenged the HDL-C hypothesis that had dominated cardiovascular prevention thinking for decades, and led straight to a reexamination of HDL-C as a target versus HDL function as the thing that actually matters.

How to Interpret the Trial Results

• The negative trials don’t mean niacin does nothing clinically relevant. They mean something more specific, and more important: raising HDL-C concentration via niacin in patients already on optimized statin therapy does not reduce cardiovascular events. A few interpretations are worth sitting with.
• HDL-C concentration vs. function. The trials may have failed because niacin raises HDL-C quantity without equivalently improving HDL cholesterol efflux capacity — the functional measure of reverse cholesterol transport that actually protects arteries. If the raised HDL particles are dysfunctional, which some evidence suggests happens with certain interventions, the concentration increase is cosmetic. Not protective.
• Already-optimized LDL context. Both trials ran in patients on statins with well-controlled LDL-C. Some researchers argue niacin’s benefit may be context-dependent: in patients with significant residual LDL-C burden not well controlled by statin, niacin’s effects on VLDL and LDL-P might offer incremental benefit invisible in trials where the primary atherogenic driver was already handled.
• Adverse effects offsetting benefits. Niacin’s impact on glucose metabolism (raising fasting glucose, worsening insulin resistance), uric acid (raising gout risk), and inflammatory markers may offset cardiovascular benefits even where the lipid effects are genuinely favorable. HPS2-THRIVE in particular — with its actual increase in adverse events, infections included — suggests niacin isn’t metabolically neutral. Far from it.
• The Lp(a) exception. Neither trial was designed to test whether niacin’s Lp(a)-lowering effect specifically drives cardiovascular benefit. Trial populations weren’t stratified by Lp(a) status. That leaves the question of whether niacin benefits high-Lp(a) patients specifically genuinely open — though absent targeted trial evidence, leaning on that hypothesis means accepting real uncertainty.

Flush and Its Management

1. Aspirin shortly beforehand: Inhibits cyclooxygenase, reducing prostaglandin synthesis. It is the most effective flush-prevention strategy in the literature, and the trials that tested it gave a single standard tablet roughly half an hour ahead of the niacin. Aspirin carries its own bleeding and gastric risks, which is why it belongs to supervised niacin programmes rather than to casual experimentation.
2. Take with food: Slows absorption, reduces peak plasma concentration, reduces flush intensity.
3. Gradual escalation from a very low starting point: Flush intensity falls as HCAR2 receptors desensitize with repeated exposure, which is why supervised niacin programmes open far below the lipid-active range and climb in small weekly increments instead of arriving there directly. Most people report minimal flush after four to six weeks of consistent exposure.
4. Extended-release formulation: Slower release, lower peak concentration, less flush — at the cost of higher hepatotoxicity risk at high doses compared to immediate-release.
5. Avoid hot beverages and alcohol immediately before or after dosing: Both increase vasodilation and worsen flush.

The niacin flush ranges from mildly annoying to genuinely alarming for the uninitiated. Understanding the mechanism makes it manageable.

Niacin activates HCAR2 receptors in skin Langerhans cells, triggering release of prostaglandin D2 (PGD2). PGD2 binds DP1 receptors in dermal blood vessels, causing vasodilation — the warmth, redness, tingling, mostly across face, neck, upper chest, forearms. Typically begins 15-30 minutes after dosing, lasts 20-90 minutes. Harmless. Uncomfortable, though. Genuinely uncomfortable, the first few times especially.

Strategies that meaningfully reduce flush intensity:

Forms of Niacin — What Each Does and Doesn’t Do

Confusion in the niacin space is compounded badly by multiple commercially available forms with different pharmacological profiles — sold interchangeably in supplement stores, as if they were the same thing. They aren’t.

• Nicotinic acid (immediate-release niacin). The active lipid-modifying form. Causes flush. Lowers triglycerides, raises HDL, lowers Lp(a). At high doses, hepatotoxicity risk is real but lower than with extended-release forms. This is the form used in most lipid research.
• Extended-release niacin (Niaspan, generic ER niacin). Prescription extended-release. Less flush than immediate-release. More hepatotoxic at high doses, due to a different metabolic pathway — more extensive first-pass hepatic metabolism via conjugation rather than simple oxidation. This is the form used in AIM-HIGH and HPS2-THRIVE. Prescription only.
• Inositol hexaniacinate (“flush-free niacin”). Marketed as delivering niacin’s benefits minus the flush. Multiple pharmacological studies have shown it doesn’t produce meaningful plasma nicotinic acid levels and doesn’t affect lipids at all. Functionally inert as a lipid intervention. The flush is mechanistically tied to the same prostaglandin response that produces the lipid effects — there’s no version of this where you get one without the other. Products marketed as flush-free niacin for cholesterol are either misleading consumers on purpose or leaning on outdated, misrepresented science.
• Niacinamide (nicotinamide). A different form of B3 entirely. No flush, no lipid effect. Other uses — skin health, some psychiatric applications at high doses, NAD+ precursor — but not a lipid-modifying agent, full stop.

For anyone considering niacin for lipid reasons: the only relevant forms are immediate-release nicotinic acid or prescription extended-release Niaspan. Everything else is either a different compound, or an inert version of this one.

The Niacin Decision Guide

1. Assess Indication: What lipid abnormality is the target? Niacin has its best evidence for triglyceride reduction and HDL-C raising. For Lp(a) reduction it’s one of few options, though outcomes data doesn’t back it. For LDL-C reduction alone, it’s inferior to statins, RYR, or ezetimibe.
2. Consider AIM-HIGH and HPS2-THRIVE Context: Already on statin therapy with well-controlled LDL-C? The evidence base for adding niacin for cardiovascular event prevention is weak. Not evidence-supported in that context.
3. Baseline Testing: Fasting glucose, HbA1c, uric acid, liver enzymes, complete lipid panel before starting. Niacin worsens insulin resistance and raises uric acid — both disqualifying if significantly elevated at baseline.
4. Understand How Niacin Gets Introduced: Immediate-release niacin is never introduced at lipid-active amounts. Supervised programmes open a long way below them, with food, climb in small weekly steps, and sometimes use aspirin ahead of the dose to blunt flush. Arriving at the trial amounts on day one is how people end up in Alan’s 2 AM situation, and the route there is a prescribing decision rather than a self-directed one.
5. Monitor During Treatment: Repeat fasting glucose, uric acid, and liver enzymes at 6 weeks, then every 3-6 months. For scale, the extended-release trials that moved triglycerides ran at 1500-2000mg daily, and the Lp(a) signal appears at higher exposures still — amounts that make the monitoring non-negotiable and the prescriber central to the whole exercise.
6. Reassess After 3 Months: Did the target lipid actually improve? Glucose and uric acid stable? Side effects acceptable? No meaningful benefit, or side effects that aren’t worth it — discontinue. If isolated hypertriglyceridemia is the goal, omega-3s are safer and similarly effective. Reconsider whether niacin was ever the right tool.

When Niacin Is Not Indicated

The clearest contraindications and cautions:

1. Diabetes or pre-diabetes (HbA1c above 5.6%): Niacin raises fasting glucose 5-10% and worsens insulin resistance. In borderline metabolic health, that’s clinically meaningful deterioration, not a rounding error. HPS2-THRIVE found increased new-onset diabetes in the niacin arm.
2. Active gout or elevated baseline uric acid: Niacin raises uric acid, potentially triggering gout attacks. History of gout, or uric acid above 7 mg/dL — niacin is inappropriately risky here.
3. Liver disease or heavy alcohol use: High-dose niacin is hepatotoxic, and any preexisting liver impairment raises that risk significantly.
4. Peptic ulcer disease: Niacin increases gastric acid secretion through prostaglandin mechanisms and can worsen peptic ulcer disease.
5. Already on adequate statin therapy: The trial evidence doesn’t support adding niacin on top, for cardiovascular event prevention.

FAQ — Niacin and Cholesterol

Q: Did the niacin trials fail because of the formulation or the concept?

A: Still debated. AIM-HIGH used prescription Niaspan (ER niacin). HPS2-THRIVE used ER niacin plus laropiprant, which added its own adverse effects on top. Immediate-release niacin hasn’t been tested in a large modern outcomes trial. Some researchers argue the concept might still work with IR niacin in a different patient population — high Lp(a), lower LDL-C. The honest answer: available RCT evidence says niacin added to statin therapy doesn’t reduce cardiovascular events, but the hypothesis hasn’t been definitively tested in every relevant context.

Q: Is niacin still prescribed clinically?

A: Much less than before AIM-HIGH and HPS2-THRIVE. Prescriptions in the US dropped dramatically after 2011-2014. It remains an option for isolated hypertriglyceridemia when omega-3s are insufficient, for HDL-C raising in specific contexts, and for Lp(a) reduction when the risk-benefit balance is favorable. No longer routinely added to statin therapy for general cardiovascular risk reduction.

Q: What about the Coronary Drug Project result — didn’t niacin reduce heart attacks?

A: The Coronary Drug Project (1970s) did show niacin monotherapy reduced non-fatal MI. But that was pre-statin, in an era when LDL wasn’t controlled by other means. The relevant modern question is whether niacin adds benefit on top of contemporary standard-of-care statin therapy — that’s what AIM-HIGH and HPS2-THRIVE tested, and found nothing. Not directly comparable contexts.

Q: If I want to raise my HDL naturally, what actually works?

A: Aerobic exercise is the most evidence-supported intervention for HDL-C raising through functional improvement, not just concentration. Weight loss, smoking cessation, moderate alcohol reduction (for heavy drinkers) also raise HDL-C. Fish oil has modest positive effects. These interventions improve HDL function, not just the number. Since function — efflux capacity — matters more than concentration for cardiovascular protection, lifestyle approaches that improve both beat niacin, which raises concentration without clear evidence of functional improvement.

Q: Is nicotinamide riboside (NR) the same as niacin for cholesterol?

A: No. NR is a NAD+ precursor studied for potential aging-related benefits. It doesn’t activate the HCAR2 receptor responsible for niacin’s lipid effects. Doesn’t lower cholesterol, raise HDL, or touch Lp(a). Entirely different use of a vitamin B3 family compound. Don’t conflate the NAD+ precursor literature with the lipid management literature — different compounds, different targets.

Alan eventually stopped the niacin after his cardiologist walked him through the AIM-HIGH results, got his glucose checked (it had climbed from 95 to 108 mg/dL fasting over his three months on niacin), and shifted to optimized diet, high-intensity exercise, and a low-dose statin that brought his full lipid panel to optimal levels. His HDL sits at 47 mg/dL now — lower than his niacin peak, but a number his cardiologist considers far less important than his ApoB of 68 mg/dL and his hs-CRP of 0.8 mg/L. The HDL target was the wrong thing to chase. Niacin was the wrong tool even for chasing it. That’s what the evidence eventually teaches, if you’re willing to listen to it.

The Broader HDL Hypothesis — a Cautionary Tale

Niacin’s trial failure is part of a broader reckoning cardiovascular researchers went through in the 2010s: multiple interventions that raised HDL-C concentration failed to reduce cardiovascular events, and some caused harm outright. Not just niacin — CETP inhibitors too, a class of drugs specifically engineered to raise HDL-C dramatically by blocking cholesteryl ester transfer protein.

Torcetrapib, the first CETP inhibitor, raised HDL-C by 70% and still failed to reduce cardiovascular events. It actually increased mortality in the ILLUMINATE trial. Later CETP inhibitors (dalcetrapib, evacetrapib) also failed to show benefit despite dramatic HDL-C elevation. Only anacetrapib, in the REVEAL trial, showed a modest benefit — and it was never pursued to regulatory approval, given tissue accumulation concerns and a modest benefit-to-cost ratio.

What this pattern taught the field, collectively: HDL-C concentration isn’t a causal factor in cardiovascular protection the way LDL-C is a causal factor in cardiovascular damage. Mendelian randomization studies using genetic variants that raise HDL-C showed no corresponding drop in cardiovascular events — unlike genetic variants that lower LDL-C, which robustly reduce events in proportion to the LDL-C reduction. HDL-C is a biomarker that correlates with cardiovascular health through confounding (metabolic fitness, exercise, non-smoking all raise HDL-C and also cut cardiovascular risk through a dozen other mechanisms), but raising HDL-C pharmacologically doesn’t replicate those mechanisms.

None of which means HDL doesn’t matter. It means HDL-C on a blood test is a poor proxy for the thing that actually matters — HDL particle quality and cholesterol efflux capacity. Someone who exercises regularly and maintains metabolic health has higher HDL-C and better HDL function. Someone who takes niacin has higher HDL-C, not necessarily better function. Same blood test. Different biology underneath.

The lesson for practical cardiovascular medicine: stop targeting HDL-C as a number to raise. Focus on the behaviors that improve both HDL function and the rest of cardiovascular health at once — and those behaviors don’t include pharmacological HDL-C manipulation with an unfavorable evidence-to-risk ratio.

What the Niacin Story Means for Self-Directed Health Management

Alan’s story, and the broader rise and fall of niacin in clinical cardiology, holds a lesson well beyond this one compound: mechanistic plausibility and favorable biomarker changes are not sufficient evidence that an intervention improves outcomes.

A humbling truth, and a recurring one. Medical history is full of interventions that made perfect physiological sense, improved the relevant biomarkers, and then failed — or caused harm — once outcomes got measured in properly designed trials. Hormone replacement therapy was given to postmenopausal women for decades on observational data and plausible mechanisms, before RCTs revealed the actual cardiovascular and cancer risks. Antioxidant supplementation was pushed for decades on mechanistic arguments about oxidative stress, before trials showed no cardiovascular benefit and some possible harm. Beta-carotene supplementation raised plasma beta-carotene exactly as expected — and raised lung cancer risk in smokers right along with it.

Niacin raised HDL-C as expected. Improved multiple lipid parameters as expected. Failed to reduce cardiovascular events when properly tested. The mechanism was sound. The biomarker improvements were real. The outcomes benefit just wasn’t there. Not a failure of science — science working exactly as it should, testing hypotheses instead of accepting plausible mechanisms as proof.

For anyone managing their own health through research and reasoning: hold mechanistic arguments with appropriate skepticism until validated by clinical outcomes data. Treat biomarker improvements as evidence of direction, not confirmation of benefit. Stay willing to update when RCT evidence contradicts the mechanistic story. Which isn’t the same as passively accepting whatever current guidelines say — guidelines lag the evidence by years. It’s about intellectual honesty. The argument “X raises Y, Y correlates with better health outcomes, therefore X improves outcomes” has a long track record of being wrong in medicine.

Outcomes data beats the logic of the mechanism, every time.

Niacin is valuable precisely as an example of this. It should make anyone more careful, not more dismissive, of compelling mechanistic arguments for interventions that haven’t been through outcomes trials. The cardiologists who prescribed niacin on the strength of the HDL-C data weren’t stupid. They were doing what seemed rational before better evidence existed. When the better evidence arrived, the rational ones updated. That’s the model. Apply it to everything on the shelf.

Practical Alternatives for Niacin’s Intended Targets

Came to niacin for a specific lipid problem — high triglycerides, low HDL-C, elevated Lp(a)? Here’s the current evidence landscape for each.

For high triglycerides (above 200 mg/dL):

1. Eliminate refined carbohydrates and added sugars — the primary dietary driver of elevated triglycerides. A 4-week elimination reliably drops triglycerides 20-40% in most people.
2. High-dose EPA+DHA omega-3s (3-4g daily) reduce triglycerides 20-40%. Prescription icosapentaenoic acid (EPA, Vascepa) at 4g daily showed cardiovascular event reduction in REDUCE-IT, though that trial is methodologically debated.
3. Diet and omega-3s insufficient? Fibrates (fenofibrate, gemfibrozil) are effective, with better triglyceride-lowering evidence than niacin.
4. Lose weight if overweight — visceral fat drives hepatic VLDL overproduction and elevated triglycerides. The metabolic driver is fat in the liver and abdomen, not the fat on the plate.

For low HDL-C (below 40 mg/dL in men):

1. Regular aerobic exercise is the most potent functional HDL improver available. 150+ minutes weekly of moderate-to-vigorous cardio raises HDL-C 5-10% and improves efflux capacity.
2. Smoking cessation, where applicable. Smoking dramatically impairs HDL function through direct oxidative effects on the particles, reducing reverse cholesterol transport efficiency.
3. Weight loss, where metabolically appropriate. Visceral fat depresses HDL-C; losing it improves the number.
4. Stop targeting HDL-C directly. Raising the number without improving the function doesn’t help — covered above. Focus on the behaviors that improve the whole metabolic picture.

For elevated Lp(a):

1. The strongest remaining argument for niacin, still compromised by the lack of outcomes evidence. RNA-based therapies (pelacarsen, olpasiran) in Phase 3 trials are the likely future here — track results and discuss eligibility with a cardiologist as they mature.
2. PCSK9 inhibitors (evolocumab, alirocumab) reduce Lp(a) 20-30% as a secondary effect and are already approved for high-risk patients with LDL-C elevations.
3. Aggressively optimize every other cardiovascular risk factor — since Lp(a) itself can’t be reliably lowered by available tools, reducing the absolute risk it multiplies is the most effective strategy on offer.

Niacin for Non-Lipid Purposes — a Note

This piece has focused on niacin in lipid management, where its clinical status is most clearly defined by trial evidence. Worth noting, briefly, that niacin has other applications entirely separate from that debate.

As a NAD+ precursor for longevity and energy metabolism: Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors that have drawn significant research attention for potential effects on metabolic aging, mitochondrial function, and neurological health. Functionally different from lipid-targeting niacin use, a distinct research question. Early-stage evidence, mostly animal and in vitro, with limited human trial confirmation as of early 2026.

Niacinamide (nicotinamide) for skin health: Topical and oral niacinamide has established use for inflammatory skin conditions and skin barrier function. Unrelated to the HDL/triglyceride debate entirely.

High-dose niacin for schizophrenia (orthomolecular psychiatry): A niche application with limited mainstream evidence but a long history of advocacy in alternative psychiatry. Not relevant to the cardiovascular/lipid discussion.

These distinctions matter because “niacin is bad, AIM-HIGH failed” shouldn’t get applied to NR or NMN supplementation for unrelated purposes. Different compounds, different targets. The cardiovascular trial evidence tells you about nicotinic acid’s lipid effects. It tells you nothing about NR and NAD+ levels or mitochondrial aging. Precision in language matters here more than it might seem.

The Practical Conclusion on Niacin for Cholesterol Management

Niacin does what it’s supposed to do to lipid numbers. Those lipid numbers don’t translate to fewer cardiovascular events when studied in properly designed trials. The side effect profile — flushing, glucose worsening, uric acid elevation, liver enzyme elevation — is real and clinically significant. For most people managing cardiovascular risk, niacin is a second- or third-tier option at best, appropriate only where better-tolerated interventions fall short and a physician has carefully weighed the risk-benefit balance.

The flush is manageable with aspirin pretreatment and dose titration — not a reason to reach for flush-free (inositol hexaniacinate) products that have no therapeutic effect whatsoever. The glucose and uric acid effects are reasons to screen carefully for pre-existing metabolic risk before starting. The trial failures are reasons to apply rigorous standards to whether niacin fits a specific indication at all.

Taking niacin for HDL-C raising as an add-on to a statin? The evidence no longer supports that. Taking it for isolated hypertriglyceridemia, and omega-3s haven’t been tried or optimized? Try those first. Taking it for Lp(a) lowering with physician oversight? Acknowledge the uncertainty, and track the emerging RNA therapy options. Taking flush-free niacin for cholesterol benefits? The evidence says there’s neither benefit nor flush in that bottle. Clearest case for stopping today, that one.

Alan’s HDL story ended not with niacin but with a better understanding of what was actually driving his cardiovascular risk. The B vitamin that was supposed to be his solution turned out to be the question that led him to better questions. That trajectory — from supplement fascination to evidence-informed management — is worth more than any single biomarker change, however impressive it looks in the short term.

Niacin Alternatives Worth Knowing

Given the clinical retreat from niacin, the interventions that replaced it or proved superior deserve a clear summary.

For triglyceride management (the clearest niacin replacement): Dietary modification first, always. Then omega-3 fatty acids, where the triglyceride evidence sits at the 3-4g EPA+DHA exposures tested in trials, whether the source is quality fish oil or prescription icosapentaenoic acid. Then fenofibrate (safer drug interaction profile than gemfibrozil, particularly with statins) for persistent hypertriglyceridemia above 500 mg/dL, or significantly elevated above 200 mg/dL with other risk factors present. Then, in rare cases, pemafibrate — a more selective PPAR-alpha agonist with a better safety profile than older fibrates — where available.

For overall cardiovascular risk in someone who’s failed or can’t tolerate statins: Ezetimibe (inhibits intestinal cholesterol absorption, reduces LDL-C 15-25%, no significant side effects in most people), bempedoic acid (a newer citrate lyase inhibitor that reduces LDL-C without muscle side effects), and PCSK9 inhibitors (injectable biologics with dramatic LDL-C lowering, expensive but increasingly accessible). None of these replace niacin’s HDL-C raising effect specifically — but that effect was the wrong target to begin with.

For the complete lipid management picture: The therapeutic hierarchy has simplified in the post-niacin era. Maximize LDL-C and ApoB lowering with the most tolerable, effective, evidence-based therapy available. Address triglycerides with diet and omega-3s. Accept that HDL-C is a biomarker worth tracking, not a target worth manipulating pharmacologically. For Lp(a), watch the RNA therapy pipeline and optimize everything else in the meantime. Cleaner, better-evidenced strategy than the HDL-targeting approach niacin was built to serve.

In medicine, as in investing, it’s often more important to know what not to do than to land on the one right answer. The niacin story gave cardiovascular medicine a clean example of what not to do: don’t substitute biomarker optimization for outcomes evidence. Don’t assume raising a “good” number pharmacologically equals the health behaviors that naturally raise it. And don’t confuse a compelling mechanism with a proven intervention. These lessons, paid for through expensive large-scale clinical trials, are available now — for the cost of reading and applying them.

The most expensive cardiovascular education available is a heart attack with “good” cholesterol numbers. The cheapest is reading the trial literature before building a supplement stack. Niacin is one of medicine’s more instructive lessons about the gap between those two paths. Use it that way — not to dismiss supplement-based thinking, but to sharpen it into something that survives contact with actual outcomes data.

That’s what Alan’s cardiologist was trying to teach him in that post-AIM-HIGH conversation. Not “you were stupid to try niacin” — niacin made sense given the lipid data available at the time. But: here’s what the properly conducted test showed, here’s how it changes what we do now, here’s what actually matters in your cardiovascular picture going forward. Science as an updating process. Medicine as applied epistemology. The best practitioners — and the best patients — treat it that way.

The number Alan chased — HDL-C of 51 mg/dL — turned out to be irrelevant to his cardiovascular outcome. The number that mattered, the one his niacin experiment distracted him from pursuing, was his ApoB: still 118 mg/dL when he started the statin that eventually brought it to 68. That’s the number that determines whether plaque forms. That’s the number whose reduction has actual RCT evidence behind it. Three months of productive niacin-driven HDL raising against six months of statin-driven ApoB reduction — there was never any real question which one was doing the important work. Sometimes the most valuable thing a failed experiment teaches is what should have been measured all along.

Cardiovascular medicine moves forward. The evidence it generates reshapes what good practice looks like. Niacin’s story isn’t one of failure — it’s a hypothesis being tested, the test failing, and medicine updating accordingly. Worth respecting that process, even when it invalidates something that seemed to make perfect sense. Especially then, really — the interventions that seem to make perfect sense and have never been rigorously tested are exactly the ones most likely to be hiding a flaw. Niacin got tested. The evidence spoke. The field listened. That’s how it’s supposed to work — for niacin, for every supplement currently on the shelf, and for every one being considered next.

Update your priors when the evidence changes. It’s the only rational thing to do.

The conversation Alan had in his cardiologist’s office after AIM-HIGH — this is what the trial showed, this is what it means for your management, this is what we’re doing instead — is the kind of medicine that saves lives. Not because it’s dramatically different from what came before, but because it’s grounded in what’s actually known rather than what’s hoped to be true. A doctor updating recommendations on new evidence isn’t inconsistency. It’s exactly how good medicine works. Same standard applies to managing personal health decisions. Evidence first. Mechanism second. Ideology last.

The Practical Framework: Applying Niacin Cholesterol Still Relevant In Real Life

References

• NIH Health Information

Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map